The Silicon Review ^Asia

A new tech developed by ICMR-National Institute of Cholera and Enteric Diseases (NICED) is now licensed by the Indian Council of Medical Research. The tech was executed by the Biotech Consortium India Limited (BCIL). It did this on behalf of ICMR and Hilleman Labs. Now coming to the disease it focuses on which is called Shigellosis, this is an infectious disease that is marked by bloody diarrhoea. It may come with or without a fever. Mainly caused due to the Shigella species that is carrying the disease along with them and has affected around 125 million patients in which there have been 160,00 deaths. The main affected ratio is around five years old.

So now the management on this disease is done through the improvement of antibiotic therapy, rehydration therapy and sanitation. Decision makers from WHO themselves say that there is a need for the Shigella vaccine and has rated this as the top priority. Furthermore, the World Health Organization feels this is the need of the hour and is considered to be a major breakthrough. With this in mind, this new step is most certainly said to change the lives of many who are undergoing this problem.